Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Inclusion Criteria: * ECOG 0-1 * histologically confirmed non-keratinizing carcinoma (WHO type II or III) of nasal pharynx * stage III-IVa （AJCC/UICC 8th ）, untreated NPC patients * NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L * ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN * creatinine\<1.5×ULN Exclusion Criteria: * recurrent or metastatic NPC patients * histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx * already received radiation or chemotherapy * pregnant or lactating women, or women of childbearing age without birth control * HIV (+) * had other cancers before * used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before * complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose * with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included) * use of massive dose of glucocorticoids within 4 weeks before enrollment * laboratory test values do not meet relevant standards within 7 days before enrollment * significantly lower functions of heart, liver, lung, kidney and bone marrow * serious or uncontrolled medical diseases or infections * participating other clinical trial in the same time * HBsAg (+) and HBV DNA \>1×10E3 copiers /mL * HCV (+) unless HCV RNA PCR(-) * with any other treatment contraindications